Leerink Partnrs Brokers Lift Earnings Estimates for NovoCure

NovoCure Limited (NASDAQ:NVCR) – Equities researchers at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of NovoCure in a report released on Tuesday, October 15th. Leerink Partnrs analyst J. Chang now anticipates that the medical equipment provider will post earnings of ($1.40) per share for the year, up from their previous forecast of ($1.42). The consensus estimate for NovoCure’s current full-year earnings is ($1.34) per share.

NovoCure (NASDAQ:NVCR) last released its earnings results on Thursday, July 25th. The medical equipment provider reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.09. The firm had revenue of $150.40 million during the quarter, compared to analysts’ expectations of $135.83 million. NovoCure had a negative net margin of 30.67% and a negative return on equity of 45.68%. NovoCure’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.54) EPS.

Several other analysts have also recently issued reports on NVCR. Wedbush reissued an “outperform” rating and set a $24.00 price objective on shares of NovoCure in a research note on Thursday, July 25th. Wells Fargo & Company lowered their price objective on shares of NovoCure from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. HC Wainwright raised shares of NovoCure from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $24.00 to $30.00 in a research note on Wednesday. Finally, Evercore ISI lowered their price objective on shares of NovoCure from $21.00 to $18.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.17.

NovoCure Stock Up 1.8 %

NVCR stock opened at $17.21 on Friday. The stock has a market capitalization of $1.85 billion, a P/E ratio of -9.51 and a beta of 0.70. The company has a debt-to-equity ratio of 1.81, a quick ratio of 6.22 and a current ratio of 6.46. NovoCure has a one year low of $10.87 and a one year high of $24.74. The company has a 50 day moving average price of $17.06 and a two-hundred day moving average price of $17.72.

Institutional Investors Weigh In On NovoCure

A number of institutional investors have recently modified their holdings of NVCR. Ridgewood Investments LLC acquired a new stake in shares of NovoCure in the 2nd quarter valued at about $28,000. Signaturefd LLC raised its stake in shares of NovoCure by 61.7% in the 2nd quarter. Signaturefd LLC now owns 1,644 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 627 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of NovoCure during the 2nd quarter valued at about $34,000. Fifth Third Bancorp bought a new stake in shares of NovoCure during the 2nd quarter valued at about $43,000. Finally, GAMMA Investing LLC grew its position in shares of NovoCure by 278.0% during the 1st quarter. GAMMA Investing LLC now owns 2,880 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 2,118 shares during the last quarter. Institutional investors and hedge funds own 84.61% of the company’s stock.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.